Read this company snapshot
Daily valuation snapshot
Royalty Pharma plc Class A Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $56.93
- Market capitalization (USD)
- $32,734,818,543.72
- Price / earnings (TTM)
- 40.17
- Price / book
- 3.35
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RPRX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RPRX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing RPRX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $56.93 |
| Market capitalization (USD) | $32,734,818,543.72 |
| Price / earnings (TTM) | 40.17 |
| Price / book | 3.35 |
No matching rows. Clear the filter to see all records.
Read RPRX's valuation metrics
Company size
Royalty Pharma plc Class A Ordinary Shares's recorded market capitalization is $32,734,818,543.72. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
RPRX's recorded P/E is 40.17: about $40.17 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
RPRX's recorded price-to-book ratio is 3.35. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Royalty Pharma plc Class A Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about RPRX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow RPRX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.